MAPS welcomes a bipartisan congressional letter urging the FDA to clarify and improve the regulatory path for psychedelic-assisted therapies

MAPS supports a bipartisan congressional letter asking the FDA to clarify and improve the regulatory pathway for psychedelic-assisted therapies. Congressional attention centers on how federal regulation can better accommodate emerging treatments while maintaining safety and scientific standards. The statement ties that request to stalled or uncertain approval routes for therapies using substances such as MDMA and psilocybin. Regulatory clarity matters for sponsors, clinicians, and patients because trial design, review expectations, and post-approval implementation all depend on consistent federal guidance. Broader momentum around psychedelics now reaches mainstream US policymaking. Bipartisan pressure on the FDA signals growing concern that current frameworks may not fit these therapies well and that clearer rules could shape research, access, and medical adoption.